Compare Realty Income Corp (O) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Realty Income Corp vs Travere Therapeutics Inc. Common Stock — how do they compare? Realty Income Corp trades at $55.64 (market cap $52.03B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Realty Income Corp is far larger — about 10.4× Travere Therapeutics Inc. Common Stock's market cap, and Realty Income Corp pays a 5.92% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Realty Income Corp for 128 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| O | TVTX | |
|---|---|---|
Market Cap | $52.03B | $5.02B |
Volume | 16,838,213 | 2,060,842 |
Sector | Real Estate | Health |
52-Week High | $67.56 | $67.52 |
52-Week Low | $53.35 | $26.79 |
Typical Hold Time | 128 Days | 0 Days |
Enterprise Value | $82.66B | $5.15B |
Dividend Yield | 5.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Realty Income (O) trades at $54.99, up 0.53% on the day, but remains in a bearish technical trend amid recent earnings misses. The stock's valuation appears elevated with a P/E of 40.14 and P/S of 8.53, though profitability is strong with a 92.56% gross margin. Recent news highlights the stock's decline as Treasury yields rise, pressuring REIT valuations, while the company maintains a robust dividend history with consistent monthly payouts.
Outlook: Moderate upside to the $64.16 consensus price target exists, supported by solid fundamentals and high analyst buy ratings, but risks include interest rate sensitivity, debt growth, and competitive pressures. The stock offers income appeal but faces near-term headwinds from macroeconomic conditions.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
